REGISTRAR OF PATENTS

	invegior, iviichaer C
	Application No.: 10
DUUD YND EIGHED	

Express Mail Cert. No.: EV 316 332 220 US Inveptor: Michael Christian Norris Application No.: 10/505,291 Attorney Docket No.: 45669-304008

J.	- HERMANIC OF DEALER VE. THE REPORT
	FORM P.1.
MACH	NUE STAMPS OR REVENUE FRANKING 5.0
	to the second se
,	OFFICIAL DATE STAMP

<b>E</b>	REPUBLIC OF SOUTH AFRICA PATENTS ACT. 1978	U COLINE IMPRESSION
	APPLICATION FOR A RATENT	4 VIII 4 WH
	AND ACKNOWLEDGEMENT OF RECEIPT (Section 30 (1) — Regulation 22)	OFFICIAL DATE STAMP
The grant	of a patent is hereby requested by the undermentic	oned applicant on the basis of the present application
filed in du	Uplicate OFFICIAL APPLICATION No.	S & F REFERENCE
21 01	893422	JP/C 628
	NAAM VERANDER 272-41 HOCOCK	INGRAM Phormaceuticals Lil
71	PHARMACEUTICA ADCOCK-INGRAM <del>LABORATORIE</del> S LIM	ITED NAAM VERANDER NAME CHANGED
	ADDRESS(ES) OF A	APPLICANT(S)
	ADCOCK-INGRAM HOUSE, 105 QUARTS	Z STREET, HILLBROW
	TITLE OF IN	/ENTION
54	PHARMACEUTICAL COMPOSITION	
RIORITY	IS CLAIMED AS SET OUT ON THE ACCOMPANYING F	ORM P.2.
	THIS APPLICATION IS FOR A PATENT OF AC	DITION TO PATENT APPLICATION NO.
	21 01	
	1.14.1	
-THI	6 APPLICATION IS A FRESH APPLICATION IN TERMS	OF SECTION 37 AND BASED ON APPLICATION NO.
	21 01	
	VI ATION IS AGGOVED AND DAY	
	ICATION IS ACCOMPANIED BY: i <del>ngle copy of a provisional or</del> two coples of a complate spec	cification of 7
-,	wings ofsheets	
3. Pub	lication particulars and abstract (Form P.B. in duplicate)	
] 4. Ac	opy of Figure of the drawings (if any) for the at	bstract
اگا 5. Assi	ignment of invention CCEP	
] 6. Cert	tified priority document(s) (State number)	
] 7. Trai	nslation of the priority document(s)	
3 8. An i	essignment of priority rights	88/1283
9. Acc	opy of the Form P.2, and the specification of S.A. Patent A	Application No. 21 01 88/1285
∐ 10. Adı	eclaration and power of attorney on Form P.3.	
_	uest for ante-dating on Form P.4.	
	uest for classification on Form P.9.	
K) 13. FO	rm P.2 in duplicate	
74		
74 ADI	PRESS FOR SERVICE: SPOOR AND FISHER, SAN	IDTON, PRETORIA, DURBAN
		RECEIVED
		OFFICIAL DATE STAMP
ated this	9th Day ofMAY 1.989	
	A 6	A STANKE
	/// * \\	

FORM P.7. (To be lodged in duplicate)

::

#### REPUBLIC OF SOUTH AFRICA PATENTS ACT, 1978

#### **COMPLETE SPECIFICATION**

(Section 30(1) - Regulation 28)

	OFFICIAL APPLICATION NO. LODGING DATE			
21	01 893422 22 9 MAY 1989			
· <u></u>	INTERNATIONAL CLASSIFICATION			
51	А 61 К			
	FULL NAMEISI OF APPLICANT(S)			
71	PHARMACEUTICALS NAAM VERANDER ADCOCK-INGRAM LABORATORIES LIMITENAME CHANGED NAAM VERANDER NAME CHANGED 272.91 ADCOCK INGRAM Pharm acceuticals Lad.			
FULL NAMEIS) OF INVENTOR(S)				
72	STUART DAVID ASHWORTH			
TITLE OF INVENTION				
54	PHARMACEUTICAL COMPOSITION			

#### - 2 -

<u> Partitura de la companya de la comp</u>

#### BACKGROUND OF THE INVENTION

PARTICIPATE STATE OF THE PARTICIPATE OF THE PARTICI

This invention relates to a pharmaceutical composition.

There are many anti-inflammatory compounds presently on the market. Among these compounds may be mentioned indomethacin, flubiprofen, ketoprofen, ibuprofen, fenoprofen, indoprofen, fenbufen, naproxen and diclophenac. These compounds are administered to humans primarily for their anti-inflammatory activity, although some of the compounds do exhibit other useful therapeutic indications.

South African Patent No. 79/6821 discloses a pharmaceutical composition comprising as a primary agent a compound selected from diclophenac, sulindac, fenbufen, naproxen, ketoprofen, indoprofen and fenoprofen, in combination with a potentiating agent which is paracetamol (acetaminophen).

South African Patent No. 84/5785 discloses a pharmaceutical composition comprising, as active ingredients, ibuprofen, paracetamol and codeine.

- 3 -

#### SUMMARY OF THE INVENTION

According to the present invention, there is provided a pharmaceutical composition comprising as active ingredients therapeutically effective amounts of an anti-inflammatory agent selected from diclophenac, sulindac, indomethacin, naproxen, piroxicam, ketoprofen, and tiaprofenic acid, and pharmaceutically acceptable salts thereof, and the analgesics paracetamol and codeine.

#### DETAILED DESCRIPTION OF THE INVENTION

The anti-inflammatory compound may be used as such or in the form of a pharmaceutically acceptable salt, for example, the sodium salt. An example of a particularly suitable salt is diclophenac sodium.

The anti-inflammatory compounds and pharmaceutically salts thereof will preferably be administered in the following daily dosages:

Anti-inflammatory	Dosage (mg)
Diclophenac	20 - 150
Sulindac	100 - 500
Indomethacin	25 - 150
Naproxen	200 - 800
Piroxicam	10 – 60
Ketoprofen	25 - 300
Tiaprofenic Acid	150 - 600

The pharmaceutical composition may be used to treat inflammation in mammals, more particularly conditions of acute

- 4 -

inflammation in mammals, more particularly conditions of acute inflammation in mammals.

The composition may be provided in the form of tablets, suspension or capsules. For tablets, the active ingredients will be mixed with suitable binders, diluents, disintegrants and lubricants. For capsules, the active ingredients will be mixed with suitable binders, diluents and lubricants and then filled into appropriate capsules. If the composition is to be a sustained release composition, the anti-inflammatory compound will be rendered sustained release by any one of a number of known methods in the art. Enteric coatings may be provided for the tablets and capsules.

The invention will be illustrated by the following examples. Example 1 is an example of a capsule containing sulindac as the anti-inflammatory compound. Examples 2 to 4 are formulations containing diclophenac sodium as the anti-inflammatory compound.

#### EXAMPLE 1 - CAPSULES

Ingredient	Amount (mg)
Sulindac	100 - 700
Paracetamol	250 - 1500
Codeine	5 - 60
Diluent/Disintegrant	1 - 100
Lubricant/Glidant	2 - 10
Lubricant	1 - 10

- 5 -

#### EXAMPLE 2 - CAPSULES

Ingredient	mg Capsule
Diclophenac Sodium	25 - 100
Paracetamol	250 - 1500
Codeine	5 - 60
Diluent/Disintegrant	0 - 200
Glidants	1 - 15
Disintegrant	0 - 20

#### EXAMPLE 3 - TABLETS

Ingredient	mg Tablet
Diclophenac Sodium	25 - 100
Paracetamol	250 - 1500
Codeine	5 - 60
Diluent	10 - 150
Disintegrant	1 - 40
Binder	5 - 100
Lubricant	5 - 20

·- 6 -

### EXAMPLE 4 - SYRUPS

P

Ingredient	mg 10ml
Diclophenac Sodium	25 - 100
Paracetamol	250 - 1500
Codeine	5 – 60
Solvents, solubilisers &	
stabilisers	10 – 50
Colouring Agents	1 - 20
Preservatives/Anti-oxidants	0,1 - 1,0

- 7 -

#### **CLAIMS**

1.

A pharmaceutical composition comprising as active ingredients therapeutically effective amounts of an anti-inflammatory agent selected from diclophenac, sulindac, indomethacin, naproxen, piroxicam, ketoprofen, and tiaprofenic acid, and pharmaceutically acceptable salts thereof and the analgesics paracetamol and codeine.

2.

A pharmaceutical composition according to claim 1 in the form of a tablet, suspension or capsule.

3.

A pharmaceutical composition according to claim 1 substantially as hereinbefore described with reference to any one of the illustrative examples.

DATED this 9th day of MAY 1989

SPOOR AND FISHER

APPLICANT'S PATENT ATTORNEYS